Isotretinoin and antidepressant pharmacotherapy: A prescription sequence symmetry analysis

Journal of the American Academy of Dermatology

Volumn 49, Issue 3, 2003, Pages 424-432

  Hersom, Kimberly ^a   Neary, Maureen P ^b   Levaux, Hugh P ^a   Klaskala, Winslow ^b   Strauss, John S ^c  

^a IQVIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c UNIVERSITY OF IOWA HEALTH CARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CHLORDIAZEPOXIDE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; ISOTRETINOIN; MAPROTILINE; MINOCYCLINE; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; PERPHENAZINE; PROTRIPTYLINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VENLAFAXINE;

ACNE; ADOLESCENT; ADULT; ARTICLE; DATA BASE; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 0041856248     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/S0190-9622(03)02087-5     Document Type: Article

References (32)

1. National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health. Questions and answers about acne. NIH Publication No. 01-4998. Available from http://www.nih.gov/niams/healthinfo/acne/acne.htm. Revised March 1999. Accessed October 2001.
2. Krowchuk DP, Lucky AW. Managing adolescent acne. Adolesc Med 2001;12:355-74.
3. Healy E, Simpson N. Acne vulgaris. BMJ 1994;308:831-3.
4. Rademaker M, Garioch JJ, Simpson NB. Acne in schoolchildren: no longer a concern for dermatologists. BMJ 1989;298:1217-9.
5. Krowchuk DP, Stancin T, Keskinen R, Walker R, Bass J, Anglin TM. The psychosocial effects of acne on adolescents. Pediatr Dermatol 1991;8:332-8.
6. Gupta MA, Gupta AK. Depression and suicidal ideation in dermatology patients with acne, alopecia areata, atopic dermatitis and psoriasis. Br J Dermatol 1998;139:846-50.
7. Pearl A, Arroll B, Lello J, Birchall NM. The impact of acne: a study of adolescents' attitudes, perceptions and knowledge. N Z Med J 1998;111:269-71.
8. Koo JY, Smith LL. Psychological aspects of acne. Pediatr Dermatol 1991;8:185-8.
9. Kellett SC, Gawkrodger DJ. The psychological and emotional impact of acne and the effect of treatment with isotretinoin. Br J Dermatol 1999;140:273-82.
10. Gupta MA, Gupta AK, Schork NJ, Ellis CN, Voorhees JJ. Psychiatric aspects of the treatment of mild to moderate facial acne: some preliminary observations. Int J Dermatol 1990;29:719-21.
11. Rubinow DR, Peck GL, Squillace KM, Gantt GG. Reduced anxiety and depression in cystic acne patients after successful treatment with oral isotretinoin. J Am Acad Dermatol 1987;17:25-32.
12. Niemeier V, Kupfer J, Demmelbauer-Ebner M, Stangier U, Effendy I, Gieler U. Coping with acne vulgaris: evaluation of the chronic skin disorder questionnaire in patients with acne. Dermatology 1998;196:108-15.
13. Mallon E, Newton JN, Klassen A, Stewart-Brown SL, Ryan TJ, Finlay AY. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol 1999;140:672-6.
14. Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol 1998;134:454-8.
15. Roaccutane periodic safety update report, Sept 1, 2000-Aug 31, 2001. Nutley (NJ); Hoffmann-LaRoche, Inc; 2001. Submitted to the European Agency for the Evaluation of Medical Products (EMEA).
16. Burrall BA. Isotretinoin: dosing, safety, and a new formulation. Proceedings of the 59th annual meeting of the American Academy of Dermatology; 2001 March 2-7; WA DC. Washington: The Academy; 2001.
17. Wysowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001;45:515-9.
18. Jacobs DG, Deutsch NL, Brewer M. Suicide, depression, and isotretinoin: is there a causal link? J Am Acad Dermatol 2001;45: S168-75.
19. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000;136:1231-6.
20. Transcripts from FDA Dermatologic and Opthalmic Drug Advisory Committee Meeting Sept 18-19, 2000. Safety issue work-up: review of all spontaneous reports of psychiatric onditions reporting period: market introduction (1982) through April 30, 1999. May 31, 2000. Nelson Robert C. Available from: http://www.fda.gov/ohrms/dockets/ac/cder00.htm#DermatologicandOphthalmic. Revised April 25, 2001. Accessed September 2001.
21. Transcripts from FDA Dermatologic and Opthalmic Drug Advisory Committee Meeting Sept 18-19, 2000. Clinical review: clinical psychiatric analysis of suicide cases, Douglas Jacobs, MD. Available from: http://www.fda.gov/ohrms/dockets/ac/cderOO.htm#Dermatologic and Ophthalmic. Revised April 25, 2001. Accessed September 2001.
22. Neary MP, Klaskala W, McLane J, Ackermann SP. Epidemiological study of adverse events in Accutane users and matched non-users: retrospective analysis of major US health plan claims database. Proceedings of the 17th International Conference on Pharmacoepidemiology; 2001 Aug 23-26; Toronto, Ontario, Canada. Toronto: The Conference; 2001.
23. Strauss JS, Leyden JJ, Lucky AW, Lookingbill DP, Drake LA, Hanifin JM, et al. Safety of new micronized formulation of isotretinoin in patients with severe recalcitrant nodular acne: a randomized trial comparing micronized isotretinoin with standard isotretinoin. J Am Acad Dermatol 2001;45:196-207.
24. Rohrback JM, Feldman SR, Krowchuk DP, Felischer AB. Incidence of acne and depressive disorders in isotretinoin users. Proceedings of the 62nd annual meeting of the Society for Investigative Dermatology; 2001 May 9-12; Washington, DC. Washington: The Society; 2001.
25. Petri H, Leufkens H, Naus J, Silkens R, van Hessen P, Urquhart J. Rapid method for estimating the risk of acutely controversial side effects of prescription drugs. J Clin Epidemiol 1990;43:433-9.
26. Cher DJ. Myocardial infarction and acute cholecystitis: an application of sequence symmetry analysis. Epidemiology 2000;11:446-9.
27. Hallas J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 1996;7:478-84.
28. Bytzer P, Hallas J. Drug-induced symptoms of functional dyspepsia and nausea; a symmetry analysis of one million prescriptions. Aliment Pharmacol Ther 2000;14:1479-84.
29. Lindberg G, Hallas J. Cholesterol-lowering drugs and antidepressants: a study of prescription symmetry. Pharmacoepidemiol Drug Safety 1998;7:399-402.
30. National Institute of Mental Health. Depression research at the National Institute of Mental Health. Available from http://www. nimh.nih.gov/publicat/depresfact.htm. Updated April 13, 1999. Accessed October 2001.
31. Petri H, de Vet HC, Naus J, Urquhart J. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 1988;7:1171-5.
32. Hallas J, Gaist D, Bjerrum L. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997;8:666-70.